Global Parkinsons Drug Market & Clinical Trial Insight 2025

Reports
Published
Number of pages
500

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
$2400
CD-ROM Mail Delivery
$3300
Hard Copy Mail Delivery
$4200
Electronic Access - Multi-User License
$4800

"Global Parkinson\'s Drug Market & Clinical Trial Insight 2025" Report Highlights:

 

  • Global Parkinson\'s Disease Prevalence & Statistics
  • Global Parkinson\'s Drug Market Opportunity: US$ 8 Billion
  • Parkinson\'s Drug Clinical Pipeline: >250 Drugs
  • Clinical Insight on Marketed Parkinson\'s Drug: 30 Drugs
  • Anti-Parkinson\'s Drugs - Availability, Dosage & Price Analysis
  • In-Depth Insight on More Than 250 Drugs In Clinical Trials

 

The parkinson\'s drug market is currently witnessing exponential growth and emerging as a huge therapeutic market segment with unexplored potential. Presence of a vast variety of therapeutics as well as development of new approaches for management of parkinson\'s disease is indicating towards a bright future of parkinson\'s drug market. This therapeutic market segment has open multiple opportunities and avenues for pharmaceutical, biotechnological and life science companies due to vast diversity in the targeting mechanism of drugs against the different symptoms of parkinson\'s such as dementia, tremor, rigidity and slow movements.

 

“Formulated with the advent of industry experts, analytical service providers and processing companies, the market of the Parkinson’s Disease drug is expected to reach US$ 8  Billion by the year 2025.”

 

The clinical pipeline of anti-parkinson\'s drug is very robust as more than 200 clinical trials are under investigation and several new drugs are about to get approved, that are different from the traditional anti-parkinson\'s drugs. The leading pharmaceutical companies are working for the development of new therapeutic drugs class for more effective and safer treatment of parkinson\'s disease. The investments related to parkinson\'s drug research and development is also increasing continuously and the subsequent approval of new anti-parkinson\'s drugs is expected in upcoming years. Currently, about 10 new drugs are in later stage of clinical development and are expected to get approval within next 3-4 years. The leading Pharmaceutical Players working in this segment are Novartis, GSK, Pfizer, Roche, UCB, etc.

 

Further, the intense research and development in parkinson\'s drug segment has led to discovery of many new compounds, which are currently showing prominent action in various phase of clinical trials. Many of the new anti-parkinson\'s drugs are expected to be a blockbuster products, once they come out of the clinical pipeline and are commercially available in the market. Currently, parkinson\'s disease is an untreatable complication and hence several research works are under investigation for the development of permanent cure of this disease. The leading pharmaceutical players are incorporating novel therapeutics such as monoclonal antibodies (Roche’s PRX-002) and CRISPR gene editing technology, for developing effective and permanent treatment of Parkinson\'s disease. So, exponential growth in the market size of anti-parkinson\'s drug is expected in upcoming years.

 

The report “Global Parkinson Drug Market & Clinical Trial Insight 2025\" provides a thoughtful insight about the market and also the various trends and the opportunities that are allied with the dynamics of the market growth. The key strategies adapted by the different market players are in a well-differentiated segment in the report. The research study provides both quantitative as well as qualitative assessment about the challenges faced by the market and the drivers leading to the growth of the market.   

1. Global Parkinson\'s Disease Prevalence & Statistics

  1.1     North America

    1.1.1United States

    1.1.2Canada

  1.2     Europe

    1.2.1United Kingdom

    1.2.2Germany

    1.2.3Russia

  1.3     Asia- Pacific

    1.3.1China

    1.3.2Japan

    1.3.3India

    1.3.4South Korea

    1.3.5Australia

    1.3.6New Zealand

 

2. Global Parkinson\'s Drug Market Analysis

  2.1     Current Market Scenario

  2.2     Global Parkinson\'s Drug Market Segmentation

    2.2.1Regional Segmentation

    2.2.2Segmentation by Products

 

3. Anti-Parkinson\'s Drugs - Availability, Dosage & Price Analysis

  3.1     Levodopa/Carbidopa Therapeutics

    3.1.1Duopa/Duodopa

    3.1.2Rytary

    3.1.3Sinemet

  3.2     Dopamine Agonist

    3.2.1Rotigotine (Neupro)

    3.2.2Pramipexole

    3.2.3Ropinirole

  3.3     MAO B Inhibitors

    3.3.1Selegiline

    3.3.2Safinamide (Xadago)

    3.3.3Rasagiline

  3.4     Catechol O-methyltransferase (COMT) inhibitors

    3.4.1            Entacapone

    3.4.2            Tolcapone

  3.5     Other Anti-Parkinson\'s Drugs

    3.5.1            Benztropine

    3.5.2            Amantidine

    3.5.3            Istradefylline (Nourianz)

    3.5.4            Rivastigmine

 

4. Global Parkinson\'s Drug Market Drivers

 

5. Challenges for Global Parkinson\'s Drug Market

 

6. Global Parkinson\'s Drug Market Future Outlook

 

7. Global Parkinson\'s Disease Drug Clinical Pipeline Overview

  7.1     By Phase

  7.2     By Drug Class

  7.3     By Mechanism of Action

  7.4     By Formulation

  7.5     By Country

 

8. Global Parkinson\'s Disease Drug Clinical Trial: Research Phase

  8.1     Overview

  8.2     Clinical Pipeline Insight

 

9. Global Parkinson\'s Disease Drug Clinical Trial: Preclinical Phase

  9.1     Overview

  9.2     Clinical Pipeline Insight

 

 

10. Global Parkinson\'s Disease Drug Clinical Trial: Clinical Phase

  10.1   Overview

  10.2   Clinical Pipeline Insight

 

11. Global Parkinson\'s Disease Drug Clinical Trial: Phase-I

  11.1   Overview

  11.2   Clinical Pipeline Insight

 

12. Global Parkinson\'s Disease Drug Clinical Trial: Phase-I/II

  12.1   Overview

  12.2   Clinical Pipeline Insight

 

13. Global Parkinson\'s Disease Drug Clinical Trial: Phase-II

  13.1   Overview

  13.2   Clinical Pipeline Insight

 

14. Global Parkinson\'s Disease Drug Clinical Trial: Phase-II/III

  14.1   Overview

  14.2   Clinical Pipeline Insight

 

15. Global Parkinson\'s Disease Drug Clinical Trial: Phase- III Phase

  15.1   Overview

  15.2   Clinical Pipeline Insight

 

16. Global Parkinson\'s Disease Drug Clinical Trial: Preregistration Phase

  16.1   Overview

  16.2   Clinical Pipeline Insight

 

17. Global Parkinson\'s Disease Drug Clinical Trial: Registered Phase

  17.1   Overview

  17.2   Clinical Pipeline Insight

 

18. Global Marketed Parkinson\'s Drugs Clinical Insight

 

19. Competitive Landscape

  19.1   Novartis

  19.2   Merck

  19.3   Pfizer

  19.4   GlaxoSmithKline plc

  19.5   Roche

  19.6   Teva Pharmaceuticals

  19.7   AbbVie Inc.

  19.8   Mylan

  19.9   Boehringer Ingelheim

  19.10 Orion Pharma

  19.11 ACADIA Pharmaceuticals Inc

Figure 1-1: Global – Patients with Parkinson s Disease (Million), 2016 & 2019

Figure 1-2: Global – Prevalence of Parkinson s Disease by Age, 2019

Figure 1-3: Global – Parkinson s Cases by Leading Countries (Million), 2019

Figure 1-4: Global – Parkinson s Cases by Leading Countries (%), 2019

Figure 1-5: Global – Parkinson s Prevalence by Gender (%), 2019

Figure 1-6: US – Number of Parkinson s Patients (Million), 2016, 2020 & 2030

Figure 1-7: US – Age Standardized Parkinson s Prevalence Rate (Per 100,000 Population), 2019

Figure 1-8: US – Parkinson s Patients by Leading States, 2019

Figure 1-9: US – Parkinson s Patients by Gender (Million), 2019

Figure 1-10: US – Total Population v/s Population with 65+ Age (Million), 2019

Figure 1-11: US – Number of Parkinson s Related Deaths & Incidence, 2017

Figure 1-12: US – Age Standardized Parkinson s Death Rate (Per 100,000 Peoples), 2017

Figure 1-13: Canada – Age Standardized Parkinson s Average Prevalence Rate (Per 100,000 Peoples), 2019

Figure 1-14: Canada – Parkinson s Patients by Gender, 2019

Figure 1-15: Canada – Parkinson s Disease Related Deaths, 2016 & 2017

Figure 1-16: Canada – Age Standardized Parkinson s Death Rate by Gender (Per 100,000 Peoples), 2017

Figure 1-17: Canada – Total Population vs Population with 65+ Age (Million), 2019

Figure 1-18: UK – Patients with Parkinson s Disease, 2015, 2018 & 2025

Figure 1-19: UK – Newly Diagnosed Cases of Parkinson s Disease, 2015, 2018 & 2025

Figure 1-20: UK – Parkinson s Patients by Countries, 2018

Figure 1-21: UK – Parkinson s Patients Share by Countries (%), 2018

Figure 1-22: UK – Newly Diagnosed Parkinson s Cases by Countries, 2018

Figure 1-23: UK – Parkinson s Patients by Age, 2018

Figure 1-24: UK – Total Population v/s Population with 65+ Age (Million), 2019

Figure 1-25: UK – Parkinson s Related Deaths, 2016 & 2017

Figure 1-26: UK – Age Standardized Parkinson s Death Rate (Per 100,000 Peoples), 2017

Figure 1-27: Germany – Parkinson s disease Patients, 2016 & 2019

Figure 1-28: Germany – Parkinson s Patients by Gender, 2019

Figure 1-29: Germany – Total Population v/s Population with 65+ Age (Million), 2019

Figure 1-30: Germany – Parkinson s related Deaths, 2016 & 2017

Figure 1-31: Germany – Age Standardized Parkinson s Death Rate by Gender, 2017

Figure 1-32: Russia – Parkinson s Affected Population, 2016 & 2019

Figure 1-33: Russia – Age Standardized Parkinson s Prevalence Rate (Per 100,000 Peoples), 2016

Figure 1-34: Russia – Age Standardized Parkinson s Death Rate (Per 100,000 Peoples), 2017

Figure 1-35: Russia - Total Population v/s Population with 65+ Age (Million), 2019

Figure 1-36: China – Parkinson s Patients (Million), 2016 & 2019

Figure 1-37: Global – Parkinson s Cases – China v/s ROW (%), 2019

Figure 1-38: China – Parkinson s Cases by Gender (Million), 2019

Figure 1-39: China – Average Age Standardized Parkinson s Prevalence & Incidence Rate (Per 100,000 Peoples), 2019

Figure 1-40: China - Age Standardized Parkinson s Death Rate (Per 100,000 Peoples), 2017

Figure 1-41: China – Total Population v/s Population over 65+ Age (Million), 2019

Figure 1-42: Japan – Average Age Standard Parkinson s Prevalence Rate (Per 100,000 Peoples), 2019

Figure 1-43: Japan – Average Age Standard Parkinson s Incidence Rate (Per 100,000 Peoples), 2019

Figure 1-44: Japan – Parkinson s Cases & Deaths, 2016

Figure 1-45: Japan – Parkinson s Related Deaths, 2016 & 2017

Figure 1-46: Japan - Age Standardized Parkinson s Death Rate (Per 100,000 Peoples), 2017

Figure 1-47: Japan - Total Population v/s Population over 65+ Age (Million), 2019

Figure 1-48: India – Age Standardized Parkinson s Prevalence & Incidence Rate (Per 100,000 Peoples), 2019

Figure 1-49: India - Parkinson s Affected Population, 2016 & 2019

Figure 1-50: India - Parkinson s related Deaths, 2016 & 2017

Figure 1-51: India - Age Standardized Parkinson s Death Rate by Gender (Per 100,000 Peoples), 2017

Figure 1-52: India - Total Population v/s Population over 65+ Age (Million), 2019

Figure 1-53: South Korea – Parkinson s Incidence & Deaths, 2016

Figure 1-54: South Korea – Parkinson s Related Deaths, 2016 & 2017

Figure 1-55: South Korea – Age Standardized Parkinson s Death Rate by Gender (Per 100,000 peoples), 2017

Figure 1-56: South Korea - Total Population v/s Population over 65+ Age (Million), 2019

Figure 1-57: Australia – Parkinson s Cases, 2016 & 2018

Figure 1-58: Australia – Age Standardized Parkinson s Prevalence Rate (Per 100,000 Peoples), 2019

Figure 1-59: Australia – Parkinson s Related Deaths, 2015, 2016 & 2017

Figure 1-60: Australia – Age Standardized Parkinson s Death Rate (Per 100,000 Peoples), 2017

Figure 1-61: Australia – Total Population v/s Population with 65+ Age (Million), 2019

Figure 1-62: New Zealand – Parkinson s Case, 2015, 2017, 2018 & 2022

Figure 1-63: New Zealand – Parkinson s Cases by Gender, 2017

Figure 1-64: New Zealand – Age Standardized Parkinson s Death Rate (Per 100,000 Peoples), 2017

Figure 1-65: New Zealand - Total Population v/s Population over 65+ Age (Million), 2019

 

Figure 2-1: Global – Parkinson s Drug Market Size (US$ Billion), 2016 - 2018

Figure 2-2: Global - Parkinson s Drug Market Size (US$ Billion), 2019 - 2025

Figure 2-3: Parkinson s Drug Market Size – Total v/s Europe (US$ Billion), 2019

Figure 2-4: Parkinson s Drug Market Share – ROW v/s Europe (%), 2019

Figure 2-5: Parkinson s Drug Market Size – Total v/s North America (US$ Billion), 2019

Figure 2-6: Parkinson s Drug Market Share – ROW v/s North America (%), 2019

Figure 2-7: Global - Parkinson s Drug Market Size by Mechanism (%), 2018

 

Figure 3-1: Duopa – FDA Approval & Patent Expiration Year

Figure 3-2: Duopa – Price of 700ml, 100ml & 1ml of Duopa 4.3-20mg/ml Suspension (US$), December’2019

Figure 3-3: Duopa – Maximum Daily, Monthly & Annual Treatment Cost for Parkinson s Treatment (US$), December’2019

Figure 3-4: Duopa – Global Sales Value (US$ Million), 2016, 2017 & 2018

Figure 3-5: Duopa – US Sales Value (US$ Million), 2016, 2017 & 2018

Figure 3-6: Duopa – Quarterly Sales Value (US$ Million), 2019

Figure 3-7: Rytray – Number of Patents Issued in Different Years

Figure 3-8: Rytray – Price for Supply of 240, 100 & Price per Unit of 23.75-95mg, 36.25-145 mg & 48.75-195mg Dose Capsules (US$), December’2019

Figure 3-9: Rytray – Price for Supply of 240, 100 & Price per Unit of 61.25-245mg Dose Capsules (US$), December’2019

Figure 3-10: Rytray – Recommended Initial & Incremented Dose for Treatment Parkinson s Patient Naïve to Levodopa Therapy, December’2019

Figure 3-11: Rytray – Global Sales Value (US$ Million), 2017 & 2018

Figure 3-12: Quarterly Sales Value (US$ Million), 2018 & 2019

Figure 3-13: Sinemet – Price of Different Dose Regimen of Sinemet Oral Tablet (US$), December’2019

Figure 3-14: Sinemet – Per Unit Price of Different Dose Regimen of Sinemet Oral Tablet (US$), December’2019

Figure 3-15: Sinemet – Recommended Initial & Maximum Dose (mg/day), December’2019

Figure 3-16: Sinemet – Per Day Treatment cost for Initial & Maximum Dose (US$), December’2019

Figure 3-17: Neupro – Different Patent Issue & Expiration Year

Figure 3-18; Neupro – Price for Supply of 30 Transdermal Films & Price per Unit (US$), December’ 2019

Figure 3-19: Neupro – Initial & Maximum Recommended Dose for Early Stage Parkinson s (mg/day), December’2019

Figure 3-20: Neupro – Initial & Maximum Recommended Dose for Late Stage Parkinson s (mg/day), December’2019

Figure 3-21: Neupro – Global Sales (US$ Million), 2017 & 2018

Figure 3-22: Neupro – Global Half Yearly Sales Value (US$ Million), 2018 & 2019

Figure 3-23: Pramipexole – Price for 90 Tablets Supply of Different Doses (US$), December’2019

Figure 3-24: Pramipexole – Price for 90 Extended Release Tablets Supply of Different Doses (US$), December’2019

Figure 3-25: Pramipexole – Recommended Initial & Maintenance Dose Using Immideate Release Tablets (mg/day), December’2019

Figure 3-26: Pramipexole – Recommended Initial & Maintenance Dose Using Extended Release Tablets (mg/day), December’2019

Figure 3-27: Ropinirole – Price for 100 Tablet Supply of Different Doses (US$), December’2019

Figure 3-28: Ropinirole – Price for 500 Tablet Supply of Different Doses (US$), December’2019

Figure 3-29: Ropinirole – Price for 30 Extended Release Tablet Supply of Different Doses (US$), December’2019

Figure 3-30: Ropinirole – Weekly Recommended Dose & Maximum Dose of Immediate Release Tablet (mg Three Times a Day), December’2019

Figure 3-31: Ropinirole – Initial & Maximum Recommended Dose for Extended Release Tablet (mg/day), December’2019

Figure 3-32: Emsam - Price for 30 Patch Supply & Price per Unit of Various Doses of Emsam Transdermal Patches (US$), December’2019

Figure 3-33: Emsam - Monthly & Annual Treatment Cost of Parkinson s Disease (US$), December’2019

Figure 3-34: Selegiline – Price for 60 Capsule Supply & per Unit Price of 5mg Capsule (US$), December’2019

Figure 3-35: Selegiline – Price for 60 Tablet Supply & per Unit Price of 5mg Tablet (US$), December’2019

Figure 3-36: Selegiline – Annual Treatment Cost using Tablet & Capsule (US$), December’2019

Figure 3-37: Xadago – Patent Issue & Expiration Year

Figure 3-38: Xadago – Price for 30 Tablet Supply & Price per Unit (US$), December’2019

Figure 3-39: Xadago – Recommended Initial & Incremented Dose For Parkinson s Treatment (mg/day), December’2019

Figure 3-40: Generic Rasagiline – Price for 30 Tablet Supply of 0.5mg & 1mg Tablet (US$), December’2019

Figure 3-41: Azilect - Price for 30 Tablet Supply of 0.5mg & 1mg Tablet (US$), December’2019

Figure 3-42: Recommended Dose for Monotherapy & Adjuvant Therapy in Concomitant  Levodopa/ NonLevodopa Patients (mg/day), December’2019

Figure 3-43: Generic Entacapone – Price for 30, 50 & 100 Tablet Supplies 200mg Tablet (US$), December’2019

Figure 3-44: Comtan - Price for 100 Tablet Supply & Price per Unit of 200mg Tablet (US$), December’2019

Figure 3-45: Entacapone – Recommended Initial & Maximum Dose (mg/day), December’2019

Figure 3-46 Entacapone – Treatment Cost per Day Using Generic & Branded Tablet (US$), December’2019

Figure 3-47: Generic Tolcapon – Price for 90 Tablet Supplies & Per Unit Price of 100mg Tablet (US$), December’2019

Figure 3-48: Tasmar - Price for 100 Tablet Supply & per Unit Price of 100mg Tablet (US$), December’2019

Figure 3-49: Tolcapone – Recommended Initial & Maximum Dose (mg/day), December’2019

Figure 3-50: Tolcapone – Treatment Cost per Day Using Generic & Branded Tablet (US$), December’2019

Figure 3-51: Generic Benztropine – Price for 10ml Supply & per Unit Price 1mg/ml Injectable Solution (US$), December’2019

Figure 3-52: Generic Benztropine – Price for 100 Tablet Supplies of 0.5mg, 1mg & 1.5mg Dose (US$), December’2019

Figure 3-53: Cogentin – Price for 10ml Supply & per Unit Price 1mg/ml Injectable Solution (US$), December’2019

Figure 3-54: Benztropine – Recommended Initial Dose & Maximum Dose (mg/day), December’2019

Figure 3-55: Amantidine – Price for 50 Capsules Supply & per Unit Price of 100mg Capsule (US$), December’2019

Figure 3-56: Amantidine – Price for 100 Tablets Supply & per Unit Price of 100mg Tablets (US$), December’2019

Figure 3-57: Amantidine – Price for 473ml, 1000ml Supplies & per Unit Price of 50mg/ml Syrup (US$), December’2019

Figure 3-58: Amantidine – Daily Treatment Cost using Syrup, Tablet & Capsules (US$), December’2019

Figure 3-59: Nourianz – Patent Issue & Expiration Year

Figure 3-60: Nourianz – Price for 90 Tablet Supply & Price per Unit of Oral Tablet (US$), December’2019

Figure 3-61: Nourianz – Recommended Initial & Maintenance Dose (mg/Day), December’2019

Figure 3-62: Nourianz – Maximum Daily, Monthly & Annual Treatment Cost (US$), December’2019

Figure 3-63: Exelon – Price for 30 Transdermal Patch Supply & Price per Unit (US$), December’2019

Figure 3-64: Generic Rivastigmine Transdermal Patch – Price for a  Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), December’2019

Figure 3-65: Exelon – Initial & Maintenance Dose for the Treatment of Parkinson s Disease

Figure 3-66: Exelon – Monthly & Annual Treatment Cost for Treatment of Parkinson s disease

Figure 3-67: Rivastigmine – Price for a Supply of 60 capsules of Different Doses (US$), December’2019

Figure 3-68: Rivastigmine – Price for Single capsule of Different Doses (US$), December’2019

Figure 3-69: Rivastigmine – Recommended Initial, Maintenance & Incremented Maintenance Dose (mg/Day), December’2019

Figure 4-1: Global Parkinson s Drug Market Drivers

 

Figure 5 -1: Challenges for Global Parkinson s Drug Market

 

Figure 7-1: Global - Parkinson s Disease  Clinical Pipeline by Phase (Number), 2020

Figure 7-2: Global - Parkinson s Drug Pipeline by Drug Class (Number), 2020 till 2025

Figure 7-3: Global - Parkinson s Drug Pipeline by Mechanism Of Action (Number), 2020 till 2025

Figure 7-4: Global - Parkinson s Drug Pipeline by Formulation (Number), 2020 till 2025

Figure 7-5: Global - Parkinson s Drug Pipeline country (Number), 2020 till 2025

 

Figure 8-1: Share of Research Phase in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 9-1: Share of Preclinical  Phase in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 10-1: Share of Clinical Phase in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 11-1: Share of Phase-I in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 12-1: Share of Phase I/II in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 13-1: Share of Phase-II in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 14-1: Share of Phase- II/III in Overall Parkinson s Drug Clinical Pipeline (%)

Figure 15-1: Share of Phase-III in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 16-1: Share of Preregistration Phase in Overall Parkinson s Drug Clinical Pipeline (%)

 

Figure 17-1: Share of Registered Phase in Overall Parkinson s Drug Clinical Pipeline (%)